President Trump signed an executive order allocating $50 million for psychedelics in mental health treatments and fast-tracking their FDA approval, while downgrading medical marijuana's classification. This shift signals a significant change in Republican drug policy, potentially opening new avenues for research and development in the pharmaceutical industry. Watch for further regulatory changes affecting the legal status of recreational marijuana.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





